Cofinimmo Valuation

Is COFB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of COFB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: COFB (€54.25) is trading below our estimate of fair value (€96.93)

Significantly Below Fair Value: COFB is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for COFB?

Key metric: As COFB is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for COFB. This is calculated by dividing COFB's market cap by their current revenue.
What is COFB's PS Ratio?
PS Ratio5.3x
Sales€391.83m
Market Cap€2.09b

Price to Sales Ratio vs Peers

How does COFB's PS Ratio compare to its peers?

The above table shows the PS ratio for COFB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.8x
C2PU Parkway Life Real Estate Investment Trust
16.7x6.6%S$2.4b
AGR Assura
7.5x4.7%UK£1.2b
PHP Primary Health Properties
6.9x-0.4%UK£1.2b
LTC LTC Properties
7.9x-2.4%US$1.6b
COFB Cofinimmo
5.3x-1.3%€2.1b

Price-To-Sales vs Peers: COFB is good value based on its Price-To-Sales Ratio (5.3x) compared to the peer average (9.8x).


Price to Sales Ratio vs Industry

How does COFB's PS Ratio compare vs other companies in the Global Health Care REITs Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
COFB 5.3xIndustry Avg. 6.8xNo. of Companies7PS03.26.49.612.816+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: COFB is good value based on its Price-To-Sales Ratio (5.3x) compared to the Global Health Care REITs industry average (6.8x).


Price to Sales Ratio vs Fair Ratio

What is COFB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

COFB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate COFB's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst COFB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€54.25
€70.54
+30.0%
7.2%€76.50€60.00n/a14
Dec ’25€56.75
€71.50
+26.0%
6.8%€76.50€60.00n/a14
Nov ’25€58.20
€71.50
+22.9%
6.8%€76.50€60.00n/a14
Oct ’25€67.20
€72.07
+7.2%
6.3%€77.00€60.00n/a14
Sep ’25€62.15
€70.36
+13.2%
7.0%€77.00€60.00n/a14
Aug ’25€61.35
€71.14
+16.0%
8.1%€80.00€60.00n/a14
Jul ’25€57.55
€72.44
+25.9%
6.7%€80.00€60.00n/a14
Jun ’25€60.25
€72.31
+20.0%
8.2%€80.00€60.00n/a14
May ’25€63.40
€72.39
+14.2%
8.2%€80.00€60.00n/a14
Apr ’25€58.35
€72.74
+24.7%
8.2%€80.00€60.00n/a14
Mar ’25€58.30
€73.53
+26.1%
7.1%€80.00€60.00n/a14
Feb ’25€65.90
€74.03
+12.3%
7.2%€82.00€60.00n/a14
Jan ’25€71.50
€74.25
+3.8%
7.7%€85.00€62.00n/a14
Dec ’24€64.60
€74.89
+15.9%
8.9%€87.00€62.00€56.7514
Nov ’24€58.85
€75.46
+28.2%
9.6%€87.00€62.00€58.2013
Oct ’24€64.10
€82.27
+28.3%
12.7%€102.00€68.00€67.2013
Sep ’24€71.85
€86.69
+20.7%
12.9%€105.00€68.00€62.1513
Aug ’24€71.70
€89.96
+25.5%
11.6%€105.00€68.00€61.3513
Jul ’24€67.65
€90.86
+34.3%
9.3%€105.00€75.00€57.5511
Jun ’24€72.65
€91.77
+26.3%
10.1%€105.00€75.00€60.2511
May ’24€84.35
€93.05
+10.3%
11.5%€110.00€75.00€63.4011
Apr ’24n/a
€93.05
0%
11.5%€110.00€75.00€58.3511
Mar ’24n/a
€95.18
0%
10.9%€110.00€75.00€58.3011
Feb ’24€84.05
€101.09
+20.3%
20.2%€155.00€75.00€65.9011
Jan ’24€84.30
€110.59
+31.2%
20.4%€155.00€80.00€71.5011
Dec ’23€83.00
€110.95
+33.7%
20.2%€155.00€80.00€64.6011

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 17:56
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cofinimmo SA is covered by 31 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert Jan VosABN AMRO Bank N.V.
Celine HuynhBarclays
Celine Soo-HuynhBarclays